N
Nirogy Therapeutics
Developing novel small molecules to target cellular transporters
About Nirogy Therapeutics
Nirogy Therapeutics, Inc. is a biotechnology firm that develops small-molecule drugs targeting cellular transporters for the treatment of diseases like cancer and autoimmune conditions. Founded in 2013 by Vincent Sandanayaka and Jaime Escobedo, the company was formerly known as Nirogyone Therapeutics. The company's name, derived from Sanskrit, means "without illness," reflecting its mission to address unmet medical needs. Vincent Sandanayaka, who serves as the President and CEO, has an extensive background in the pharmaceutical industry. Another co-founder, Ronald DePinho, serves on the Sporos strategic advisory board.
The company's core business revolves around its drug discovery platform, which leverages computational modeling, medicinal chemistry, and biology to target solute carrier (SLC) transporters. These proteins, embedded in cell membranes, are crucial for physiological functions such as nutrient uptake and waste disposal, which are often dysregulated in various diseases. Historically, SLCs have been difficult to drug due to their complex structures. Nirogy's platform is designed to overcome these challenges and has the potential to address over 450 druggable targets.
The business model is focused on developing a pipeline of first-in-class medicines. The company generates revenue through research grants and venture capital funding to advance its programs through preclinical and clinical development, with the ultimate goal of commercializing its therapies. In January 2021, Nirogy officially launched with a $16.5 million Series A financing round co-led by Santé Ventures and Sporos Bioventures. This followed a $1.94 million grant in August 2020. The company's lead program targets monocarboxylate transporters (MCTs) to inhibit lactate transport in cancer cells. This approach has a dual effect: it directly hinders cancer cell metabolism and also enhances anti-tumor immunity by altering the tumor microenvironment. Preclinical studies have shown that these inhibitors are effective both as a standalone therapy and in combination with other immunotherapies. The company had aimed to advance this lead program into clinical trials in 2022. Beyond oncology, Nirogy's pipeline includes programs for immunology. According to a PitchBook profile, the company is listed as 'Out of Business' as of December 31, 2024.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 3.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, DT and LS
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jan 2021 | $17M | $66M | Sporos Bioventures · Sante Ventures | — |
| GRANT✓Other financing | Sep 2020 | $2M | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Nirogy Therapeutics is 220 monthly website visits, down 48.8% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Nirogy Therapeutics in the Natick ecosystem
The Nirogy Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Sporos Bioventures
Sante Ventures
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nirogy Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nirogy Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








